论文信息 - Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy - 字舞流文

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy

K. Thiel | Jianling Bi | Yuping Zhang | E. Devor | A. Newtson | K. Leslie | G. Dixit | T. Maretzky | D. Santillan | Kristina W. Thiel | Haley A Losh | Kristen L. Coleman | Thorsten Maretzky | Haley A. Losh